GGrantIndex
Sort

25,944 grants matching neurodegeneration

Longitudinal Relationships Among Sleep, Cognition and Alzheimer's Disease Biomarkers: Discerning Causal Associations, Mediators and Susceptibility

$3,217,148
Susan S Redline · Brigham And Women'S Hospital · R01 · FY2021 · AG

Characterization of Antigen-Specific Immune Response in ALS

$3,213,011
Wassim Elyaman · Columbia University Health Sciences · RF1 · FY2025 · NS

Genetic and clinical studies of Gaucher disease and other lysosomal disorders

$3,211,711
Ellen Sidransky · National Human Genome Research Institute · ZIA · FY2022 · HG

Mechanisms regulating neurodegeneration and repair

$3,207,428
Claire Le Pichon · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2023 · HD

Dysfunctional lipid metabolism and peroxidation in chronic pain and neurodegeneration

$3,199,356
Christopher Ramsden · National Institute On Aging · ZIA · FY2025 · AG

Achieving specificity in imaging neurodegeneration with visible light Optical Coherence Tomography

$3,198,179
Vivek Jay Srinivasan · New York University School Of Medicine · OT2 · FY2025 · OD

Mapping amyloid, tau, and neurodegeneration markers with neuropsychiatric phenotypes and genotypes in Alzheimer's disease continuum using machine learning

$3,188,901
Ganesh Chand · Washington University · RF1 · FY2025 · AG

Role of PS1 in neurodegeneration

$3,188,744
Oksana Berezovska · Massachusetts General Hospital · RF1 · FY2019 · AG

A Systems Approach to Targeting Innate Immunity in AD

$3,188,314
Nilufer Ertekin-Taner · Mayo Clinic Jacksonville · U01 · FY2021 · AG

Escitalopram for Agitation in Alzheimer Disease

$3,183,018
Constantine G Lyketsos · Johns Hopkins University · R01 · FY2016 · AG

Mitochondrial stress responses in neurodegeneration

$3,176,786
Derek Narendra · National Institute Of Neurological Disorders And Stroke · ZIA · FY2024 · NS

AMP-Kinase as a target for neuroprotection in AD

$3,175,735
Michael K Lee · University Of Minnesota · RF1 · FY2019 · AG

Brain - Plasma Proteomics Biomarker Discovery and Validation in the US and UK

$3,174,907
Allan I Levey · Emory University · RF1 · FY2017 · AG

UCSD Alzheimer's Disease Research Center P50

$3,174,023
Douglas R Galasko · University Of California, San Diego · P50 · FY2014 · AG

Circadian dysfunction and Epigenetic alterations in the pathogenesis of Alzheimer's Disease

$3,173,392
Paula Alejandra Desplats · University Of California, San Diego · RF1 · FY2019 · AG

Diabetes and brain amyloid in middle aged Hispanics

$3,169,894
Jose A Luchsinger · Columbia University Health Sciences · R01 · FY2022 · AG

Dysfunction of the Autophagy-Lysosomal Pathway as a Common Mechanism of Neurodegeneration

$3,162,400
Steven M Finkbeiner · J. David Gladstone Institutes · RF1 · FY2017 · AG

Genetics of Early Onset Parkinson's Disease: Mitochondrial Drivers of PD Pathogenesis

$3,154,937
Derek Narendra · National Institute Of Neurological Disorders And Stroke · ZIA · FY2021 · NS

Upstream pathogenesis in familial and sporadic frontotemporal dementia and motor neuron disease

$3,153,019
William W Seeley · University Of California, San Francisco · RF1 · FY2025 · NS

Role of Retrotransposon Activity in Neurodegeneration and Alzheimer's Disease

$3,148,529
John M. Sedivy · Brown University · P01 · FY2025 · AG

Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's Disease

$3,135,849
Arthur W Toga · University Of Southern California · P01 · FY2025 · AG

The regulation of synaptic transmission and neural circuit function

$3,133,617
Wei Lu · National Institute Of Neurological Disorders And Stroke · ZIA · FY2021 · NS

Diabetes and brain amyloid in middle aged Hispanics

$3,132,512
Jose A Luchsinger · Columbia University Health Sciences · R01 · FY2023 · AG

Prevention of Alzheimer Dementia and Cognitive Decline

$3,115,773
John C S Breitner · Seattle Inst For Biomedical/Clinical Res · U01 · FY2009 · AG

Mechanisms, modeling and therapies of retinal and macular neurodegeneration

$3,114,999
Anand Swaroop · National Eye Institute · ZIA · FY2020 · EY